Table 3

Population attributable risks associated with physical inactivity in different geographical regions

OutcomeCentral asia, Middle East and North AfricaCentral and Eastern EuropeEast and
Southeast
Asia
High-income
Asia pacific
High-income
Western
countries
Latin
America and
Caribbean
OceaniaSouth
Asia
Sub-Saharan
Asia
Prevalence (95% CI)*†32.8 (31.0 to 35.2)23.4 (20.9 to 28.0)17.3 (15.8 to 22.1)35.7 (34.4 to 37.0)36.8 (34.6 to 38.4)39.1 (37.8 to 40.6)16.3 (14.3 to 20.7)33.0 (23.0 to 51.7)21.4 (19.1 to 23.3)
PARsemi (95% CI)
 All-cause mortality8.4 (6.5 to 10.4)6.2 (4.6 to 7.8)4.6 (3.4 to 6.0)9.1 (7.0 to 11.2)9.3 (7.2 to 11.5)9.9 (7.7 to 12.2)4.4 (3.2 to 5.6)8.5 (5.0 to 12.3)5.7 (4.3 to 7.1)
 CVD Mortality9.0 (7.4 to 10.6)6.6 (5.2 to 8.0)4.9 (3.9 to 6.1)9.7 (8.1 to 11.4)9.9 (8.3 to 11.7)10.5 (8.7 to 12.4)4.7 (3.6 to 5.8)9.0 (5.5 to 12.8)6.0 (3.9 to 7.2)
 Coronary heart disease5.9 (4.2 to 7.6)4.3 (3.0 to 5.7)3.2 (2.2 to 4.3)6.4 (4.6 to 8.2)6.5 (4.7 to 8.4)6.9 (5.0 to 8.9)3.0 (2.1 to 4.1)5.9 (3.3 to 9.0)3.9 (2.8 to 5.2)
 Stroke5.9 (3.5 to 8.5)4.3 (2.5 to 6.2)3.2 (1.8 to 4.7)6.4 (3.8 to 9.2)6.5 (3.9 to 9.4)6.9 (4.1 to 10.0)3.0 (1.7 to 4.4)5.9 (2.9 to 9.6)3.9 (2.2 to 5.7)
 Hypertension1.9 (1.1 to 2.8)1.4 (0.8 to 2.0)1.0 (0.6 to 1.5)2.1 (1.2 to 3.0)2.2 (1.3 to 3.1)2.3 (1.3 to 3.3)1.0 (0.6 to 1.4)1.9 (1.0 to 3.2)1.3 (0.7 to 1.8)
 Type 2 diabetes5.3 (3.8 to 6.9)3.8 (2.7 to 5.1)2.9 (2.0 to 3.9)5.7 (4.0 to 7.5)5.9 (4.2 to 7.7)6.2 (4.5 to 8.1)2.7 (1.8 to 3.7)5.3 (3.0 to 8.0)3.5 (2.5 to 4.6)
 Bladder cancer2.6 (−1.4 to 7.1)1.8 (−1.0 to 5.2)1.4 (−0.8 to 3.8)2.8 (−1.5 to 7.7)2.9 (−1.7 to 7.9)3.0 (−1.7 to 8.5)1.3 (−0.7 to 3.6)2.6 (−1.5 to 7.5)1.7 (−0.9 to 4.7)
 Breast cancer*3.5 (1.6 to 5.4)2.2 (0.9 to 3.5)1.5 (0.6 to 2.5)3.3 (1.5 to 5.3)3.7 (1.6 to 5.8)3.8 (1.8 to 6.0)1.8 (0.8 to 2.9)3.7 (1.4 to 6.7)2.2 (1.0 to 3.5)
 Colon cancer3.5 (1.4 to 5.7)2.5 (1.0 to 4.2)1.9 (0.7 to 3.2)3.8 (1.6 to 6.1)3.9 (1.6 to 6.4)4.1 (1.7 to 6.7)1.8 (0.7 to 2.9)3.5 (1.3 to 6.3)2.3 (0.9 to 3.7)
 Endometrial cancer*3.5 (−0.6 to 8.0)2.2 (−0.3 to 5.1)1.5 (−0.3 to 3.5)3.3 (−0.5 to 7.6)3.7 (−0.6 to 8.3)3.8 (−0.6 to 8.7)1.8 (−0.3 to 4.2)3.7 (−0.6 to 9.3)2.2 (−0.4 to 5.0)
 Oesophageal cancer8.4 (−3.0 to 24.4)6.2 (−2.1 to 17.9)4.6 (−1.7 to 13.7)9.1 (−3.2 to 26.6)9.3 (−3.3 to 27.7)9.9 (−3.5 to 29.2)4.4 (−1.6 to 12.9)8.5 (−2.9 to 25.9)5.7 (−2.0 to 16.6)
 Gastric Cancer8.1 (−0.3 to 19.0)5.9 (−0.2 to 14.2)4.5 (−0.2 to 10.6)8.8 (−0.6 to 20.5)9.0 (−0.4 to 21.6)9.6 (−0.5 to 22.3)4.2 (−0.2 to 10.1)8.2 (−0.3 to 20.3)5.5 (−0.2 to 12.8)
 Renal Cancer8.4 (2.8 to 14.9)6.2 (2.1 to 11.1)4.6 (1.6 to 8.3)9.1 (3.0 to 16.3)9.3 (3.1 to 16.8)9.9 (3.4 to 17.4)4.4 (1.4 to 7.9)8.5 (2.5 to 16.2)5.7 (1.8 to 10.2)
 Dementia9.5 (2.8 to 17.5)7.0 (2.2 to 12.9)5.3 (1.6 to 9.7)10.3 (3.2 to 18.8)10.5 (3.3 to 19.1)11.1 (3.6 to 20.4)5.0 (1.5 to 9.3)9.6 (2.6 to 19.1)6.4 (2.0 to 11.8)
 Depression8.4 (1.5 to 16.9)6.2 (1.0 to 12.4)4.6 (0.8 to 9.4)9.1 (1.6 to 18.4)9.3 (1.5 to 18.7)9.9 (1.7 to 20.0)4.4 (0.8 to 9.0)8.5 (1.3 to 18.1)5.7 (1.0 to 11.4)
  • *The prevalence of insufficient physical activity among women (Central Asia, Middle East and North Africa: 39.9%; 95% CI 37.9% to 42.7%; Central and Eastern Europe: 24.7%; 95% CI 21.7% to 33.9%; East and Southeast Asia: 16.9%; 95% CI 14.9% to 25.7%; high-income Asia Pacific: 38.3%; 95% CI 37.4% to 42.6%; high-income Western: 42.3%; 95% CI 39.1% to 45.4%; Latin America and Caribbean: 43.7%; 95% CI 42.9% to 46.5%; Oceania: 20.3%; 95% CI 18.8% to 28.7%; South Asia: 43.0%; 95% CI 29.6% to 74.9%; sub-Saharan Africa: 24.8%; 95% CI 21.8% to 27.2%) was applied to compute the PARsemi for breast cancer and endometrial cancer.

  • †Prevalence estimates were obtained from Guthold et al. 4

  • CVD, cardiovascular disease; PAR, population attributable risk.